[Lutetium-177 radiolabeled somatostatin analogs in neuroendocrine tumors]
Gonzalez L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001427
Spanish
Authors' recommendations:
CONCLUSIONS
Moderate quality evidence showed that the use of 177Lu-DOTATATE in patients with well-differentiated advanced neuroendocrine tumors of the midgut (small bowel, appendix and ascending colon), with somatostatin receptor overexpression and progressed to first-line treatment might increase overall survival, progression-free survival and objective response rate.
Very low-quality evidence showed that the use of Lutetium-177 radiolabeled somatostatin analogs in patients with neuroendocrine tumors of another location might present the same benefit
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Neuroendocrine Tumors
- Antineoplastic Agents
- Octreotide
- Organometallic Compounds
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.